Weleader Biomedical Co (ROCO:7713) Research & Development: NT$0 Mil (TTM As of Dec. 2025)


ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
47 GF Score
Price NT$70.10
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co Research & Development?

Weleader Biomedical Co ROCO:7713 -1.54% 47 Research & Development is NT$0 Mil as of Dec. 2025. GuruFocus rates ROCO:7713 with a GF Score™ of 47/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Weleader Biomedical Co's Research & Development for the three months ended in Dec. 2025 was NT$0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0 Mil.

Weleader Biomedical Co  (ROCO:7713) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Weleader Biomedical Co Research & Development Related Terms

Weleader Biomedical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co Research & Development Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:7713
47GF Score
Weleader Biomedical Co Ltd ROCO:7713
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Weleader Biomedical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$0 Mil mean?
Weleader Biomedical Co (ROCO:7713) has a Research & Development of NT$0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Weleader Biomedical Co and its competitors.
Is Weleader Biomedical Co's Research & Development too high?
Weleader Biomedical Co's current Research & Development is NT$0 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Research & Development compare to ABT and SYK?
Weleader Biomedical Co's Research & Development of NT$0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current Research & Development is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current Research & Development of NT$0 Mil. The current Research & Development is NT$0 Mil. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Research & Development is NT$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score

Get the complete analysis for ROCO:7713

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.10
Price